Physician profile
Ratnavali Kolla
NPI 1174617625
$15,287.94
in general payments reported to CMS, 2019-2025
53 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $993 · 2021: $2,060 · 2022: $2,678 · 2023: $2,416 · 2024: $2,713 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,724.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,594.58 | 2019-2025 | |
| Abbvie INC. | $1,446.39 | 2021-2025 | |
| Biogen, INC. | $1,200.05 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $1,092.32 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Neurelis, INC. | $651.05 | 2020-2025 | Valtoco |
| Ucb, INC. | $637.78 | 2019-2025 | Briviact, Nayzilam |
| Eisai INC. | $581.99 | 2019-2025 | |
| Lundbeck LLC | $577.62 | 2020-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $495.57 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Emd Serono, INC. | $473.31 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $443.03 | 2023-2024 | Aptiom |
| Celgene Corporation | $402.97 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $344.41 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $277.27 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $274.82 | 2019-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratnavali Kolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.